Evolution of CCS and Sustainability
In Biopharmaceutical Manufacturing
Technik
Abstract
Process closure, contamination control and sustainability are all key factors in modern facility designs for commercial scale Advanced Therapy Medicinal Products (ATMP) manufacturing. Such facilities require optimised and streamlined operations while facilitating a high degree of flexibility for multi-product/multi-modal operation to ensure efficient operation while minimising the Cost of Goods (CoG). Process closure and contamination control strategies ensure minimised segregation requirements and cleanroom grades which in turn maximises sustainability by reduced footprint and energy consumption.
Correspondence:
Stephen Judd
Arcadis, Lake Drive, Citywest Business Campus, D24 E1CY Dublin 24
stephen.judd@arcadis.com
 | Stephen Judd is a Chartered Chemical Engineer and Fellow of Engineers Ireland. He is an experienced Technical Manager and Principal Process Engineer with 18 years of experience in process engineering and facility design. He has significant experience in process technology selection and has experience across the full project life cycle from feasibility study to commissioning and qualification. Stephen has authored or co-authored a number of technical papers, including a paper on multi-modal facility design published in Pharmaceutical |
